Ocular Therapeutix Announces NDA Resubmission of Dextenza

BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 29, 2018-- Ocular Therapeutix ™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye,...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news